pubmed-article:18604473 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18604473 | lifeskim:mentions | umls-concept:C0927232 | lld:lifeskim |
pubmed-article:18604473 | lifeskim:mentions | umls-concept:C0206660 | lld:lifeskim |
pubmed-article:18604473 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
pubmed-article:18604473 | lifeskim:mentions | umls-concept:C0085405 | lld:lifeskim |
pubmed-article:18604473 | lifeskim:mentions | umls-concept:C0205087 | lld:lifeskim |
pubmed-article:18604473 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:18604473 | pubmed:dateCreated | 2008-10-2 | lld:pubmed |
pubmed-article:18604473 | pubmed:abstractText | Central nervous system (CNS) germinoma is a curable tumor and its recurrence rate after initial therapy may be approximately 10% or higher. This study elucidates the time-course of recurrence and results of salvage therapy. Twenty-five patients with recurrent germinoma treated at Hokkaido University Hospital were retrospectively reviewed. The median age at initial treatment was 12 years (range: 8-37). All patients had been tumor-free for at least 6 months after the initial treatment. The median follow-up period was 134 months (range: 44-338). The median age at first recurrence was 18 years and the median time to the first recurrence was 50 months. Among the patients, 9 (36%) had the first recurrence at 60 months or later. The latest recurrence in a patient occurred 230 months after the initial treatment. The results of salvage therapy were estimated in all 25 patients. Seventeen patients (68%) were salvaged and were tumor-free at the final observation. The remaining 8 patients died of disease. At first recurrence, 11 patients were treated using radiation therapy with or without surgery and 7 out of the 11 patients died due to the recurrent tumor. On the other hand, 13 patients who received salvage chemotherapy and radiotherapy were tumor-free at the last follow-up. In conclusion, late recurrence is not a rare event in patients with CNS germinoma. To identify a true cure rate of this disease, a 10-year or longer observation period may be required. As a salvage therapy, platinum-based chemotherapy followed by wide-field low-dose radiation therapy appears to be effective. | lld:pubmed |
pubmed-article:18604473 | pubmed:language | eng | lld:pubmed |
pubmed-article:18604473 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18604473 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18604473 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18604473 | pubmed:month | Nov | lld:pubmed |
pubmed-article:18604473 | pubmed:issn | 0167-594X | lld:pubmed |
pubmed-article:18604473 | pubmed:author | pubmed-author:AoyamaHidefum... | lld:pubmed |
pubmed-article:18604473 | pubmed:author | pubmed-author:ShiratoHiroki... | lld:pubmed |
pubmed-article:18604473 | pubmed:author | pubmed-author:IkedaJunJ | lld:pubmed |
pubmed-article:18604473 | pubmed:author | pubmed-author:SawamuraYutak... | lld:pubmed |
pubmed-article:18604473 | pubmed:author | pubmed-author:KamoshimaYuut... | lld:pubmed |
pubmed-article:18604473 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:18604473 | pubmed:volume | 90 | lld:pubmed |
pubmed-article:18604473 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18604473 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18604473 | pubmed:pagination | 205-11 | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:meshHeading | pubmed-meshheading:18604473... | lld:pubmed |
pubmed-article:18604473 | pubmed:year | 2008 | lld:pubmed |
pubmed-article:18604473 | pubmed:articleTitle | Late recurrence and salvage therapy of CNS germinomas. | lld:pubmed |
pubmed-article:18604473 | pubmed:affiliation | Department of Neurosurgery, Hokkaido University Hospital, North-15, West-7, Kita-ku, Sapporo 060-8638, Japan. kamoshima2002@yahoo.co.jp | lld:pubmed |
pubmed-article:18604473 | pubmed:publicationType | Journal Article | lld:pubmed |